The @EU_Commission has approved our therapy as the first and only treatment in the European Union for non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. Read more: https://t.co/3PMMCu4nff

Join us at the @Jefferies Healthcare Conference and @Evercore Healthcare Conference to hear how we’re innovating for the future of healthcare. Learn more: https://t.co/ZosWibk5An

Video Description: Video highlighting Q3 quarterly earnings.

Our commitment to patients and continued efforts in research and discovery have powered our Q3 2025 results. Learn about our highlights from this quarter. $INSM

We’re honored to be No. 1 on @ScienceMagazine’s Top Employers list for the fifth year in a row, showcasing our collaborative, people-first culture and commitment to innovating for those with serious diseases.

We’re pleased to announce the European Medicine Agency’s CHMP adopted a positive opinion on our investigational therapy for the treatment of non-cystic fibrosis bronchiectasis (NCFB) Read more: https://t.co/2dnNEEOXpY

Next week, we’ll be at #CHEST2025. Learn more about the data we’ll be presenting: https://t.co/TTmo37M7xq

Our new clinical trials website is built from the ground up through real conversations with trial participants, caregivers, and healthcare professionals. Learn more: https://t.co/fr1qhAf8XY #CountUsIn

Next week, we’ll be at the #ERSCongress sharing updates from across our pipeline. Learn more: https://t.co/ehdeawWEQb

Meet us at the @WellsFargo Healthcare Conference and the @MorganStanley Healthcare Conference to hear how we are innovating for the future. Learn more: https://t.co/0VE08GjNcL

The @FDA has approved the first-ever treatment indicated for non-cystic fibrosis bronchiectasis in adult & pediatric patients 12 years of age & older. Read more in our press release: https://t.co/fjMfHLVsOa & see here for full prescribing information: https://t.co/n96yxOuYWO

Video description: Video highlighting Q2 quarterly earnings.

Our Q2 2025 earnings showcase continued growth and momentum. See what drove our success this quarter. $INSM

We were honored to have Her Royal Highness The Princess Royal @RoyalFamily join us to open our new lab at Babraham Research Campus, Cambridge, UK. The site expands our global footprint and R&D efforts, strengthening our commitment to support patients with serious diseases.

Our latest Responsibility Report highlights our commitment to patients, our people, our communities, and our planet, while operating our business with the highest degree of transparency and integrity. Read the report:

We’re sharing positive topline results from our Phase 2b study in pulmonary arterial hypertension. Read more: https://t.co/CTt7WbdCk7

We’re headed to the @GoldmanSachs Healthcare Conference, sharing insights and business updates. Tune in to our webcast on Wednesday: https://t.co/cJMhMEmO7f

We’re off to #BIO2025! Are you progressing early clinical-stage programs that could with an aim to shape the future of serious and rare disease innovation? Reach out to our Business Development team here:  https://t.co/AaqPSEDvyV

Meet us at the @BankofAmerica Securities 2025 Healthcare Conference! We're sharing what’s ahead for Insmed this year and beyond. Tune in to our webcast tomorrow: https://t.co/uQi1Wti4ey #BofAHC25

Thank you, @S2S_Org, for your dedication to developing inclusive and diverse workplaces. Earlier this #BlackHistoryMonth, we launched our new employee resource group, BEING (Black Employees at Insmed Networking Group), as part of our commitment to prioritizing DE&I efforts.